肝细胞癌组织miR-139水平及其靶基因功能的生物信息学分析

doi:10.3969/j.issn.1672-5069.2017.05.012

摘要/Abstract

摘要： 目的探讨肝细胞癌（HCC）组织miR-139水平及其临床意义，并对其潜在的靶基因进行生物信息学分析，为miR-139在HCC发病机制中的作用研究提供理论基础。方法通过分析国际癌症和肿瘤基因图谱（TCGA）HCC数据库，比较HCC组织与癌旁组织mir-139水平，分析不同临床和病理学（TNM）分期肿瘤组织mir-139水平差异及其与患者生存之间的关系。通过mirTarBase数据库获取经实验证实的miR-139靶基因，并利用DAVID生物信息数据库对miR-139靶基因进行Gene Ontology功能富集分析及Kyoto Encyclopedia of Genes and Genomes信号转导通路富集分析。结果 HCC组织mir-139水平（143.12±117.55）显著低于癌旁组织【（486.48±145.18）g，P＜0.01】；随着TNM分期增加，癌组织mir-139水平呈逐渐下降趋势（I期、II期、III期、IV期分别为161±104、124.1±132.5、128±128.5、91.08±77.88，P<0.01）；癌组织mir-139水平与TNM分期呈负相关（r=-0.2563，P<0.001）；随着肿瘤T分期的增加，癌组织mir-139水平呈逐渐下降趋势（I期、II期、III期、IV期分别为159.8±101.8、121.3±129.2、135.3±131.5、72.57±48.52，P<0.01），且肿瘤组织mir-139水平与HCC T分期呈负相关（r=-0.2586，P<0.001），而与淋巴结转移（N分期）或远处转移（M分期）无显著性相关（均P>0.05）；肿瘤组织mir-139水平与患者生存呈正相关，将癌组织mir-139水平由低到高分为4个区间，其中位生存时间分别为16.05 m、16.12 m、24.05 m 和24.19 m，组间差异具有统计学意义（Log-rank，P<0.001）；miR-139靶基因功能主要富集于与启动子结合、RNA聚合酶II介导转录和细胞内信号通路传递等分子功能上，相关信号通路主要富集于各种肿瘤相关信号通路、B细胞受体信号通路、Ras信号通路和T细胞受体信号通路传递等。结论 HCC组织miR-139水平降低，且与患者临床分期和生存呈负相关。miR-139靶基因功能显著富集于转录调节和肿瘤相关信号通路传递，提示miR-139在HCC的发生、发展中起到潜在的抑癌基因作用，并可能作为新的治疗靶点和预后标志物。

关键词: 肝细胞癌, miR-139, 癌症和肿瘤基因图谱, 基因实体论

Abstract: Objective The aim of this study was to investigate the implication of miR-139 in hepatocellular carcinoma（HCC） and the bioinformatics analysis of its perimentally validated targets genes. Methods By analyzing the data of HCC in The Cancer Genome Atlas（TCGA） database，we compared the miR-139 levels in HCC tissues and its adjacent liver tissues and analyzed the association between miR-139 levels with pathological stages and survivals of patients. We also retrieved the experimentally validated target genes from the mirTarBase database，and the gene ontology（GO） and the Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analysis were made. Results Levels of miR-139 in HCC tissues（143.12±117.55） was significantly lower than that in adjacent tissues 【（486.48±145.18），P<0.01】；The patients were stratified into 4 groups based on the levels of mir-139 and the median survival in each groups from low to high were 16.05 m，16.12 m，24.05 m and 24.19 m，respectively，and there was a significant difference among different groups （Log-rank，P<0.001）；Go function analysis revealed that miR-139 target genes were mainly regulating binding with promoters and intracellular signaling transduction and KEGG analysis indicated that these genes were mainly involved in cancer-related pathways，B and T cell receptor signaling and Ras signaling pathway. Conclusion miR-139 levels is down-regulated in HCC and is negatively correlated with pathological stages and survival of patients（both P<0.05）. Bioinformatics analysis suggest that miR-139 contributes to cancer development mainly through regulating gene transcription and cancer-related signaling pathways. The present study indicates that miR-139 plays an inhibitory role in formation and development of HCC.

Key words: Hepatoma, miR-139, The Cancer Genome Atlas, Gene ontology

梁亮,张寅斌，昝瑛，张扬，张淑群. 肝细胞癌组织miR-139水平及其靶基因功能的生物信息学分析[J]. 实用肝脏病杂志, 2017, 20(5): 554-558.

Liang Liang，Zhang Yinbin，Zan Ying，et al.. Implication of miR-139 in hepatocellular carcinoma and bioinformatics analysis of its perimentally validated targets genes[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 554-558.

参考文献

[1] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012. Ca Cancer J Clin，2015，65（2）:87-108.
[2] 张杰，段伯焕，朱功兵. 肝细胞癌患者外科手术根治术后生存分析. 实用肝脏病杂志，2017，20（1）：93-96.
[3] Hao M，Zang M，Zhao M，et al. Serum high expression of mir-214 and mir-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget，2016，7（15）:19589-19600.
[4] 郝清亚，王以浪，姚登福，等. 肝癌患者血清microRNA-21水平变化. 实用肝脏病杂志，2014，17（1）:68-70.
[5] Cai L，Cai X. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma. Diagnost Pathol，2014，9:1000.
[6] Wang Z，Yang H，Ren H. MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of navigator-3. Biochem Biophys Res Commun，2015，464（4）:1228-1234.
[7] Qiu G，Lin Y，Zhang H，et al. MiR-139-5p inhibits epithelial-mesenchymal transition，migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.Biochem Biophys Res Commun，2015，463（3）:315-321.
[8] 裴丽玲，李建生，任维华. miRNAs与肝细胞癌发生研究进展. 实用肝脏病杂志，2014，17（2）:221-224.
[9] Fan Q，He M，Deng X，et al. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct，2013，31（4）:319-324.
[10] Gu W，Li X，Wang J. MiR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. Oncol Rep，2014，31（1）:397-404.
[11] Wong CCL，Wong CM，Tung EKK，et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology，2011，140（1）:322-331.
[12] Chou CH，Chang NW，Shrestha S，et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database.Nucleic Acids Res，2016，44（1）:239-247.
[13] 杨秀珍，耿爱文，肖丽，等. 慢性乙型肝炎合并脂肪肝临床与肝组织病理学分析. 实用肝脏病杂志，2017，20（1）:101-102.
[14] Goodman ZD. Neoplasms of the liver.Mod Pathol，2007，20（1）:49-60.
[15] Bartel DP. MicroRNAs:genomics，biogenesis，mechanism，and fun-
ction. Cell，2004，v116（2）:281-297.
[16] MacFarlane LA，Murphy PR. MicroRNA:Biogenesis，function and role in cancer. Curr Genomics，2015，11（7）:537-561.
[17] Maoa R，Zou F，Yang L，et al.The loss of miR-139-5p promotes colitis-associated tumorigenesis by mediating PI3K/AKT/Wnt signaling. Int J Biochem Cell Biol，2015，69:153-161.
[18] Wang H，Yan X，Ji LY，et al. MiR-139 functions as an antioncomir to repress glioma progression through targeting IGF-1 R，AMY-1，and PGC-1β. Technol Cancer Res Treat，2016[ahead of print].
[19] Zou F，Mao R，Yang S，et al. Targeted deletion of miR-139-5p activates MAPK，NF-κB and STAT3 signaling and promotes intestinal inflammation and colorectal cancer. FEBS J，2016，283（8）:1438-1452.
[20] Wang X，Wang X. Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucl Acid Res，2006，34（5）:1646-1652.